title: Solifenacin in the treatment of urgency and  other symptoms of overactive bladder:  results from a randomized, double-blind,  placebo-controlled, rising-dose trial.
abstract: OBJECTIVE
  To examine the effects of the antimuscarinic agent solifenacin on urinary urgency, using a range of novel and established outcome measures, as urgency is the principal symptom of the overactive bladder syndrome (OAB).
  
  
  METHODS
  The study (SUNRISE, solifenacin in the treatment of urgency symptoms of OAB in a rising dose, randomized, placebo-controlled, double-blind, efficacy trial) was a randomized, double-blind, 16-week, placebo-controlled, multicentre study of solifenacin 5/10 mg in 863 patients with symptoms of OAB for > or = 3 months. The primary efficacy variable was the change from baseline to endpoint in the number of episodes of severe urgency with or without urgency incontinence per 24 h, as measured using the Patient Perception of Intensity of Urgency Scale, grade 3 + 4. Secondary efficacy variables included patient-reported outcomes for bladder condition, urgency bother and treatment satisfaction. A 3-day voiding diary was used to record micturition frequency and episodes of urgency and incontinence. A 7-day diary was used to assess speed of onset of effect.
  
  
  RESULTS
  Solifenacin 5/10 mg was significantly more effective than placebo in reducing the mean number of episodes of severe urgency with or without incontinence per 24 h from baseline to endpoint (-2.6 vs -1.8, P < 0.001). There were also statistically significant differences in favour of solifenacin 5/10 mg over placebo for all secondary variables measured at endpoint, including patient-reported outcomes. There was a significant improvement in urgency as early as day 3 of treatment. Treatmente-mergent adverse events with solifenacin 5/10 mg were mainly mild or moderate in severity, and only led to discontinuation in 3.6% of patients.
  
  
  CONCLUSIONS
  Solifenacin significantly reduced the number of urgency episodes and the extent of urgency bother, and was well tolerated; it was effective as early as day 3 of treatment.
authors.affiliation: King's College Hospital, Department of Urogynaecology, London, UK. lcardozo@compuserve.com
authors.forename: Linda
authors.initials: L
authors.lastname: Cardozo
authors.forename: Elke
authors.initials: E
authors.lastname: Hessdörfer
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Milani
authors.forename: Pedro
authors.initials: P
authors.lastname: Arañó
authors.forename: Luc
authors.initials: L
authors.lastname: Dewilde
authors.forename: Mark
authors.initials: M
authors.lastname: Slack
authors.forename: Ted
authors.initials: T
authors.lastname: Drogendijk
authors.forename: Mark
authors.initials: M
authors.lastname: Wright
authors.forename: John
authors.initials: J
authors.lastname: Bolodeoku
mesh_terms: D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011812:Quinuclidines / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy*; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate